Market Overview

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis to 2023 -


The "Global
Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker,
Technology, and Indication) & Market Forecast to 2023"

report has been added to's

The report provides information about the current and future market
scenario of the Global ADCs Market. The report also highlights the major
drivers, such as increasing incidences of cancer and advances in linking
technologies, for the Global Antibody Drug Conjugates Market.
Furthermore, the report also gives information related to the
commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and

Antibody Drug Conjugates are the fastest growing class of oncology
therapeutics. These are monoclonal antibody based therapies which have
achieved great success in the field of cancer treatment, primarily when
used with cytotoxic drugs. ADC is a class of therapeutics which
harnesses the antigen-selectivity of monoclonal antibodies to deliver
the highly potent cytotoxic drugs to antigen expressing tumor cells.

The use of monoclonal antibody directed delivery confers a therapeutic
index to highly potent cytotoxic drugs, increasing both the efficacy and
safety of therapy. Such novel anti-cancer drugs are being used these
days to target cancers, while minimizing the exposure of healthy tissue.
The recent approval of four ADCs in the global market and a strong
pipeline of such drugs, highlight the potential for new therapeutic
innovations in this industry.

Moreover, few hindrances, such as high cost of production cost, lack of
experienced manufacturers and regulatory challenges, which are slowing
down the growth of the Global ADCs Market, have also been mentioned in
the report. In addition, the report also highlights various trends and
developments taking place in this market.

Furthermore, in this report, we have structured the information
regarding ADCs at various stages of clinical development that are under
research or in collaboration, and those individually being developed by
companies. The pipeline chapter provides in depth analysis of ADCs of
companies as well as research organizations by clinical phase,
indications for which they are being developed, type of linker, drugs,
and technology. Additionally, the study provides all-inclusive current
analysis of various ADCs in advanced as well as early stages of
development. Moreover, our report places an emphasis on the strategic
alliances that can impact industry's growth.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates


5.2 Kadcyla

5.3 Mylotarg

5.4 Besponsa

6. Antibody Drug Conjugates Pipeline Analysis

6.1 By Companies

6.1.1 By Clinical Phase

6.1.2 By Indication

6.1.3 By Drug

6.1.4 By Type of Linker

6.1.5 By Technology

6.2 By Research Organizations

6.2.1 By Phase

6.2.2 By Indication

6.2.3 By Drug

6.2.4 By Type of Linker

6.2.5 By Technology

7. Drivers and Challenges

7.1 Drivers

7.1.1 Rising Global Cancer Epidemics

7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC

7.1.3 Efforts towards Patent Protection to Drive ADC Market

7.1.4 Increasing Demand for Antibody Drug Conjugates

7.2 Challenges

7.2.1 Production Hurdles and Cost

7.2.2 Inadequacy of Experienced Manufacturers

7.2.3 Regulatory Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

8.1 By Companies

8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex

8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.

8.1.3 Indatuximab Ravtansine/BT-062 - Biotest AG

8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals

8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.

8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.

8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.

8.2 By Research Organizations

8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug
Research, Netherlands

8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University

9. Trends and Developments

9.1 ADC at the Forefront of Treating Hematological Malignancies

9.2 ADCs Proving Advantageous for Breast Cancer Patients

10. Strategic Alliances in the Global Antibody Drug Conjugates

11. Competitive Assessment

11.1 Seattle Genetics, Inc.

11.2 F. Hoffman-La Roche Ltd.

11.3 Pfizer Inc.

11.4 ImmunoGen, Inc.

11.5 Bayer AG

11.6 Takeda Pharmaceutical Company Limited

11.7 Immunomedics, Inc.

11.8 Oxford BioTherapeutics

11.9 Concortis Biotherapeutics

11.10 NBE-Therapeutics

For more information about this report visit

View Comments and Join the Discussion!